Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study

Ítems similars

• Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial()
  per: Jansåker, Filip, et al.
  Publicat: (2019)
• Mutational change of CTX‐M‐15 to CTX‐M‐127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient
  per: Nielsen, Karen Leth, et al.
  Publicat: (2019)
• Retrospective study of men with E. coli UTI treated with an oral antibiotic, and risk for a new prescription or hospital admission due to UTI
  per: Jansåker, Filip, et al.
  Publicat: (2020)
• The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections – a randomized, double-blinded, placebo-controlled clinical trial study protocol
  per: Jansåker, Filip, et al.
  Publicat: (2016)
• “Population structure of drug-susceptible,—resistant and ESBL-producing Escherichia coli from community-acquired urinary tract”
  per: Hertz, Frederik Boëtius, et al.
  Publicat: (2016)